The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://bookmarkextent.com/story22727480/retatrutide-vs-tirzepatide-a-comparative-analysis